Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q2 2020 · 10-Q
Revenue$0.00$0.00— vs Q2 2019 Net Income-$1.60M-$1.60MN/M vs Q2 2019 EPS Diluted-$0.43-$0.43N/M vs Q2 2019 Operating Income-$1,262,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
derived
ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end